tiprankstipranks
Trending News
More News >
NurExone Biologic (TSE:NRX)
:NRX
Canadian Market

NurExone Biologic (NRX) Income Statement

Compare
12 Followers

NurExone Biologic Income Statement

Last quarter (Q3 2024), NurExone Biologic's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, NurExone Biologic's net income was $-3.50M. See NurExone Biologic’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ 17.66B$ 20.85B$ 13.61B$ 6.63B$ 4.07B
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 3.33B$ 60.61B$ ―$ 1.57B$ 1.37B
EBITDA
$ 14.80B$ 17.66B$ 9.64B$ 4.30B$ 2.43B
Operating Income
$ 8.89B$ 13.66B$ 6.52B$ 1.99B$ -69.00M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ 15.00B$ 12.56B$ 5.52B$ 721.00M$ -862.00M
Per Share Metrics
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

NurExone Biologic Earnings and Revenue History